NSCLC

July 11, 2017

FDA Grants Orphan Drug Status to TPX-0005 for Non-small Cell Lung Cancers with Gene Mutations

News

U.S. regulators have granted orphan drug status to TP Therapeutics’ TPX-0005 as a treatment for non-small cell lung cancers with certain gene mutations, according to a company press release. The Federation Drug ... Read more

July 6, 2017

Mutation Burden and PD-L1 Levels Can Help Predict Patient’s Response to Opdivo, Study Finds

News

Genetic characterization and the detection of PD-1 ligand protein (PD-L1) levels in non-small cell lung cancers (NSCLC) can help oncologists identify those who may benefit the most from Opdivo (nivolumab) as ... Read more

June 26, 2017June 26, 2017

FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer

News

The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for the treatment of patients with metastatic non-small cell lung cancer ... Read more

June 22, 2017

Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage

News

A clinical trial exploring entinostat in combination with Merck’s Keytruda (pembrolizumab) in non-small cell lung cancer (NSCLC) patients who progressed despite checkpoint-blocking treatment, met the required response threshold to advance ... Read more

June 13, 2017

Keytruda Increases Survival of Lung Cancer Patients, Compared with Standard Chemo, Update Shows

lung cancer, News

Keytruda (pembrolizumab) reduced the risk of non-small cell lung cancer patients dying by 37 percent, compared with standard chemotherapy, according to updated information from a Phase 3 clinical trial. Sixty-one percent ... Read more

May 30, 2017

FDA Gives Green Light to Zykadia as First-line Therapy for ALK-positive NSCLC

News

The U.S. Food and Drug Administration has approved Norvartis‘ Zykadia (ceritinib) to be used as first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic ... Read more

May 25, 2017

EU Panel Recommends Approval of Zykadia as First-line Treatment for ALK-Positive NSCLC

News

Zykadia (ceritinib) was recommended for approval in Europe by the EMA‘s Committee for Medicinal Products for Human Use (CHMP) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) ... Read more

May 12, 2017May 12, 2017

FDA Puts Keytruda on Accelerated Approval Track as Combo Lung Cancer Treatment

News

The U.S. Food and Drug Administration has put Merck‘s Keytruda (pembrolizumab) on an accelerated approval track as a combo treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The accelerated track ... Read more

May 11, 2017May 11, 2017

Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer

News

Biocept and the Addario Lung Cancer Medical Institute (ALCMI) will collaborate on a clinical study assessing the efficacy of Biocept’s Target Selector platform to detect circulating biomarkers in patients with lung ... Read more

April 26, 2017April 26, 2017

Tagrisso Receives Full FDA Approval for Treatment of T790M-positive NSCLC

News

AstraZeneca has announced that Tagrisso (osimertinib), a medication that’s been in development for the treatment of non-small cell lung cancer (NSCLC), recently received full approval from the U.S. Food and ... Read more